世界中西医结合杂志2026，Vol.21Issue(7)：1340-1346,7.DOI:10.13935/j.cnki.sjzx.260711
千金苇茎汤加减联合NP化疗方案治疗中晚期非小细胞肺癌肺郁痰瘀证患者的临床观察
Efficacy of Modified Qianjin Weijing Decoction Combined with NP Chemotherapy Regimen in the Treatment of Advanced Non-Small Cell Lung Cancer with Pulmonary Depression and Phlegm Stasis Syndrome
摘要
Abstract
Objective To observe the clinical efficacy of Modified Qianjin Weijing Decoction combined with the vinorelbine+cisplatin(NP)chemotherapy regimen in the treatment of advanced non-small cell lung cancer(NSCLC)with pulmonary depression and phlegm stasis syndrome.Methods A total of 104 NSCLC patients admitted to the Department of Integrated Traditional Chinese and Western Medicine Oncology,Shaanxi Cancer Hospital from December 2023 to November 2024 were enrolled and randomly divided into a control group and a treatment group using a random number table method,with 52 cases in each group.The control group received the NP chemotherapy regimen,while the treatment group received Modified Qianjin Weijing Decoction combined with the NP chemotherapy regimen.Patients in both groups were treated for two chemotherapy cycles.The two groups were compared in terms of traditional Chinese medicine(TCM)syndrome efficacy,solid tumor efficacy,TCM syndrome scores before and after treatment,quality of life improvement rate,prognostic index[systemic immune-inflammatory index(SII)and prognostic nutritional index(PNI)],and adverse reactions.Results The improvement rate of TCM syndrome efficacy in the treatment group was 90.38%(47/52),which was higher than that in the control group(25.53%,12/51)(P<0.05).The objective response rate of solid tumor efficacy in the treatment group was 32.69%(17/52),compared with 23.53%(12/51)in the control group(P>0.05);the disease control rate in the treatment group was 92.31%(48/52),which was higher than that of the control group(78.43%,40/51)(P<0.05).After treatment,there was no significant difference in the TCM syndrome scores compared to before treatment in the control group(P>0.05),while the TCM syndrome scores in the treatment group decreased significantly compared to those before treatment(P<0.05);moreover,all TCM syndrome scores in the treatment group were significantly lower than those in the control group(P<0.05).The quality of life improvement rate in the treatment group was 44.23%(23/52),which was higher than that in the control group(19.61%,10/51)(P<0.05).After treatment,the SII values in both groups decreased compared with those before treatment(P<0.05);the SII value in the treatment group was lower than that in the control group(P<0.05).There was no statistically significant difference in PNI value compared with before treatment in the control group(P>0.05);the PNI value in the treatment group increased significantly compared with that before treatment(P<0.05);and the PNI value in the treatment group was significantly higher than that in the control group(P<0.05).The incidence of myelosuppression,gastrointestinal reactions,and liver function impairment in the treatment group were significantly lower than those in the control group(P<0.05);there was no statistically significant difference in the incidence of renal function impairment between the two groups(P>0.05).Conclusion Modified Qianjin Weijing Decoction combined with the NP regimen has attenuating toxicity and enhancing efficacy effect in the treatment of advanced NSCLC,and is beneficial for improving the disease control rate and patients'quality of life.关键词
非小细胞肺癌/肺郁痰瘀证/NP方案/千金苇茎汤/免疫炎症指数/预后营养指数Key words
non-small cell lung cancer/pulmonary depression and phlegm stasis syndrome/NP chemotherapy regimen/Qianjin Weijing Decoction/immune inflammatory index/prognostic nutritional index分类
医药卫生引用本文复制引用
马仰仰,陈晓泉,吴昊,黄振家..千金苇茎汤加减联合NP化疗方案治疗中晚期非小细胞肺癌肺郁痰瘀证患者的临床观察[J].世界中西医结合杂志,2026,21(7):1340-1346,7.基金项目
陕西省中医药管理局(2022-QCYZH-003) （2022-QCYZH-003）
